Vaxart (FRA:NB11) Accounts Payable: €20.9 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:NB11 Vaxart Inc FRA:NB11
50 GF Score
Price €0.38
! 3 Warning Signs
View Full Analysis

What is Vaxart Accounts Payable?

Vaxart FRA:NB11 50 Accounts Payable is €20.9 Mil as of Mar. 2026. GuruFocus rates FRA:NB11 with a GF Score™ of 50/100. The stock has 3 warning signs investors should review.

Vaxart's Accounts Payable for the quarter that ended in Mar. 2026 was €20.9 Mil.

Vaxart's quarterly Accounts Payable declined from Sep. 2025 (€45.2 Mil) to Dec. 2025 (€18.4 Mil) but then increased from Dec. 2025 (€18.4 Mil) to Mar. 2026 (€20.9 Mil).

Vaxart's annual Accounts Payable increased from Dec. 2023 (€1.5 Mil) to Dec. 2024 (€6.7 Mil) and increased from Dec. 2024 (€6.7 Mil) to Dec. 2025 (€18.4 Mil).

Vaxart Accounts Payable Historical Data

* Premium members only.

The historical data trend for Vaxart's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vaxart Accounts Payable Chart

Vaxart Annual Data
Trend Jun16 Jun17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Accounts Payable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.43 5.21 1.45 6.65 18.36

Vaxart Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Accounts Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 15.37 9.20 45.22 18.36 20.92
FRA:NB11
50GF Score
Vaxart Inc FRA:NB11
Accounts Payable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vaxart Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Frequently Asked Questions Learn more about Accounts Payable →
What does a Accounts Payable of €20.9 Mil mean?
Vaxart (FRA:NB11) has a Accounts Payable of €20.9 Mil as of Mar. 2026. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Vaxart and its competitors.
Is Vaxart's Accounts Payable too high?
Vaxart's current Accounts Payable is €20.9 Mil. Overall, Vaxart has a GF Score™ of 50/100, reflecting its overall financial health beyond just this single metric.
How does Vaxart's Accounts Payable compare to VTVT and SPRB?
Vaxart's Accounts Payable of €20.9 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Biotechnology company?
A good Accounts Payable depends on the Biotechnology industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Vaxart and its competitors. Vaxart's current Accounts Payable is €20.9 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vaxart stock overvalued right now?
Vaxart (FRA:NB11) has a current Accounts Payable of €20.9 Mil. The current Accounts Payable is €20.9 Mil. Vaxart's overall GF Score™ is 50/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For Vaxart (FRA:NB11), the current Accounts Payable is €20.9 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Vaxart Business Description

Other Exchanges VXRT:USA
Address 170 Harbor Way, Suite 300, South San Francisco, CA, USA, 94080
Vaxart Inc is a clinical-stage biotechnology company. It focuses on the development of oral recombinant vaccines based on its Vector Adjuvant Antigen Standardized Technology to protect against a wide range of infectious diseases. The products under its tablet pipeline consist of the treatment of Coronavirus, Norovirus, Seasonal Influenza, RSV(respiratory syncytial virus), and HPV(Human papillomavirus) Therapeutic. It operates in a single segment, which is the discovery and development of oral recombinant protein vaccines. Geographically, all the business activity functions through the region of the United States.
50GF Score

Get the complete analysis for FRA:NB11

Accounts Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.38
Price